Tedizolid (TR-701): a new oxazolidinone with enhanced potency.

Published

Journal Article (Review)

INTRODUCTION: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. AREAS COVERED: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. EXPERT OPINION: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.

Full Text

Duke Authors

Cited Authors

  • Kanafani, ZA; Corey, GR

Published Date

  • April 2012

Published In

Volume / Issue

  • 21 / 4

Start / End Page

  • 515 - 522

PubMed ID

  • 22324973

Pubmed Central ID

  • 22324973

Electronic International Standard Serial Number (EISSN)

  • 1744-7658

Digital Object Identifier (DOI)

  • 10.1517/13543784.2012.660250

Language

  • eng

Conference Location

  • England